Pharmaceuticals, Biotechnology and Life Sciences
SBTI ID
40003091
Localisation
Germany
Europe
Secteur d'activité
Pharmaceuticals, Biotechnology and Life Sciences
Type d'organisation
Corporate
Dernière mise à jour
15/05/2025
Statut
Classification
1.5°C
Année cible
2030
Statut
Targets set
Classification
1.5°C
Année cible
2050
Overall Net-Zero Target: LTS Lohmann Therapie-Systeme AG commits to reach net-zero greenhouse gas emissions across the value chain by 2050. Near-Term Targets: LTS Lohmann Therapie-Systeme AG commits to reduce absolute scope 1 and 2 GHG emissions 50% by 2030 from a 2023 base year. LTS Lohmann Therapie-Systeme AG also commits to reduce absolute scope 3 GHG emissions from purchased goods and services, fuel- and energy-related activities, waste generated in operations, employee commuting, and end-of-life treatment of sold products 25% within the same timeframe. Long-Term Targets: LTS Lohmann Therapie-Systeme AG commits to reduce absolute scope 1 and 2 GHG emissions 90% by 2050 from a 2023 base year. LTS Lohmann Therapie-Systeme AG also commits to reduce absolute scope 3 GHG emissions 90% within the same timeframe.
Statut
Targets setAnnée cible
2050
Statut
BA1.5 memberDate d'engagement
19/01/2023
The targets covering greenhouse gas emissions from company operations (scopes 1 and 2) are consistent with reductions required to keep warming to 1.5°C
LEI
529900Z0OSVTBAO1IJ04
Source : Science Based Targets initiative | Données publiques